Palliative Medicine Handbook
search     associated sites     
Menu
Index

Open All | Close All

Archived Topics
Log in
Username:
Password:
You only need to log in if you wish to post messages, or are an editor.
Register
I forgot my password
Preferences
Page Layout
Text Style
Standards Compliance


Valid XHTML 1.0 Valid CSS 2.1

Website

 

 

Powered by MySQL

 

Powered by PHP

Edition/Revision: 1.0
Validated 1 Aug 2001

« updated version available » 

Drug Interactions

The potential for drug interactions is high in palliative care due to polypharmacy.[1] The following are some selected drug interactions which are pertinent to palliative care prescribing.

Warfarin

The anticoagulation effect of warfarin can be affected by many drugs.[2] Anticoagulation may increase with:

  • dextropropoxyphene (co-proxamol)
  • NSAIDs
  • amiodarone
  • erythromycin, clarithromycin
  • quinolone antibiotics (e.g. ciprofloxacin)
  • metronidazole
  • fluconazole, itraconazole, miconazole, ketoconazole
  • stanozolol
Amiodarone

A number of drugs used concomitantly with amiodarone increase the risk of ventricular arrhythmias and the advice is to avoid them:

  • tricyclic antidepressants (amitriptyline etc.)
  • phenothiazines, haloperidol
  • flecainide
  • quinine
  • erythromycin (parenteral)

The low doses of haloperidol (antiemetic) and TCAs (neuropathic pain) used in palliative care probably carry a low risk, but one that cannot be dismissed.[3]

MAOIs (antidepressants) and selegiline

There is a serious and potentially fatal interaction (serotonin syndrome[4]) between pethidine and MAOIs.[5,6] A similar reaction is seen with selegiline, an MAO-B inhibitor.

No adverse interaction normally occurs in patients on MAOIs given morphine, but there are two isolated and unexplained reports of patients on MAOIs who showed hypotension, marked in one case and accompanied by unconsciousness (and rapidly and effectively reversed by naloxone). Some very limited evidence also suggests that no interaction occurs with methadone.[5]

The concurrent use of MAOIs and phenothiazines is usually safe and effective. The exception appears to be levomepromazine (methotrimeprazine) which has been implicated in two fatal reactions with pargyline and tranylcypromine.[5]

Anticonvulsants

Carbamazepine[7,8] levels are increased (risk of toxicity) with:

  • dextropropoxyphene[9,10] (co-proxamol)
  • clarithromycin, erythromycin
  • fluoxetine, fluvoxamine

Phenytoin levels are increased (toxicity) by:

  • clarithromycin, metronidazole, trimethoprim
  • fluconazole, miconazole
  • omeprazole
  • fluoxetine, fluvoxamine
  • aspirin
  • diltiazem, nifedipine
  • amiodarone

Carbamazepine and phenytoin levels are decreased (risk of fits) by corticosteroids.

Carbamazepine, phenytoin and phenobarbital can reduce the efficacy of corticosteroids. This two-way interaction[11,12] is common when managing patients with cerebral tumours.

Antifungal drugs (imidazoles)

(Fluconazole, miconazole, itraconazole, and ketoconazole).

  • all enhance warfarin anticoagulation
  • fluconazole, miconazole increase phenytoin levels
  • fluconazole, miconazole increase sulphonylureas e.g. gliclazide, glibenclamide (risk of hypoglycaemia)
  • fluconazole increases celecoxib levels[13] → halve celecoxib dose
  • itraconazole, ketoconazole and possibly fluconazole increase sedation with midazolam
PPIs (proton pump inhibitors)
  • omeprazole increases blood diazepam levels (increase sedation)
  • omeprazole enhances anticoagulation effect of warfarin
Metronidazole
  • disulfiram-like reaction with alcohol
  • enhances anticoagulation with warfarin
  • increases phenytoin blood levels (toxicity)
  • increases blood levels of fluouracil (5-FU) increasing toxicity
SSRI antidepressants
  • fluoxetine, fluvoxamine increase carbamazepine or phenytoin blood levels (toxicity)
  • fluoxetine increases plasma levels of flecainide
  • serious reaction with MAOIs, selegiline (serotonin syndrome)[4]
  • increased serotonergic effects with St John's wort (avoid)
St John's wort
  • increased serotonergic effects with SSRIs (avoid)
  • reduced anticoagulant effect of warfarin
  • reduced plasma levels of carbamazepine, phenytoin, phenobarbital (risk of fits)
  • reduced plasma levels of digoxin
Dextropropoxyphene (in co-proxamol)
  • increases blood levels of carbamazepine up to 6-fold[9,10] (toxicity)
  • enhanced anticoagulation effect of warfarin

Regular paracetamol may also affect warfarin anticoagulation.[14-20]

Torsades de pointes

An increasing number of drugs have been recognised to prolong the QT interval and potentially cause torsades de pointes, a serious cardiac arrhythmia.[21] A register of drugs that cause QT prolongation is available on the internet at http://www.torsades.org


References

  1. Bernard SA, Bruera E. Drug interactions in palliative care. (review) J Clin Oncol 2000;18(8):1780-99  [abstract]  *
  2. Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. An update. (review) Clin Pharmacokinet 1996;30(6):416-44  [abstract]  *
  3. Jackson T, Ditmanson L, Phibbs B. Torsade de pointes and low-dose oral haloperidol. (review) Arch Intern Med 1997;157(17):2013-5  [abstract]  *
  4. Sporer KA. The serotonin syndrome. Implicated drugs, pathophysiology and management. (review) Drug Saf 1995;13(2):94-104  [abstract]  *
  5. Stockley IH. Drug Interactions. 4th ed. London: Pharmaceutical Press, 1996
  6. Browne B, Linter S. Monoamine oxidase inhibitors and narcotic analgesics. A critical review of the implications for treatment. (review) Br J Psychiatry 1987;151:210-2  [abstract]  *
  7. Pippenger CE. Clinically significant carbamazepine drug interactions: an overview. Epilepsia 1987;28(S3):S71-6  [abstract]  *
  8. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. (review) Clin Pharmacokinet 1996;31(3):198-214  [abstract]  *
  9. Oles KS, Mirza W, Penry JK. Catastrophic neurologic signs due to drug interaction: Tegretol and Darvon. Surg Neurol 1989;32(2):144-51  [abstract]  *
  10. Yu YL, Huang CY, Chin D, et al. Interaction between carbamazepine and dextropropoxyphene. Postgrad Med J 1986;62(725):231-3  [abstract]  [FULL TEXT FREE]  *
  11. Gambertoglio JG. Corticosteroids and anticonvulsants. Drug Interactions Newsletter 1983;3:55-58  *
  12. Wong DD, Longenecker RG, Liepman M, et al. Phenytoin-dexamethasone: a possible drug-drug interaction. (letter) JAMA 1985;254(15):2062-3  [more]  *
  13. Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. (review) Clin Pharmacokinet 2000;38(3):225-42  [abstract]  *
  14. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279(9):657-62  [abstract]  *
  15. Amato MG, Bussey H, Farnett L, et al. Acetaminophen and risk factors for excess anticoagulation with warfarin. (comment) JAMA 1998;280(8):695-6; author reply 697  [more]  *
  16. Eliason BC, Larson W, Singer DE, et al. Acetaminophen and risk factors for excess anticoagulation with warfarin. (comment) JAMA 1998;280(8):696-7  [more]  *
  17. Estrada C. Acetaminophen and risk factors for excess anticoagulation with warfarin. (comment) JAMA 1998;280(8):695; author reply 697  [more]  *
  18. Gray CD. Acetaminophen and risk factors for excess anticoagulation with warfarin. (comment) JAMA 1998;280(8):695; author reply 697  [more]  *
  19. Pedell L. Acetaminophen and risk factors for excess anticoagulation with warfarin. (comment) JAMA 1998;280(8):696; author reply 697  [more]  [full text subs]  *
  20. Riser J, Gilroy C, Hudson P, et al. Acetaminophen and risk factors for excess anticoagulation with warfarin. (comment) JAMA 1998;280(8):696; author reply 697  [more]  [full text subs]  *
  21. Yap YG, Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation. (editorial) BMJ 2000;320(7243):1158-9  [more]  [FULL TEXT FREE]  *
Edition/Revision: 1.0
Created 1 Aug 2001
Validated 1 Aug 2001 by Ian Back
Home | Hits | Credits | Contact
Tue 09 Feb 2010 12:12:06 GMT
Palliative Care Matters